十五名平均年齡為五十四歲，已經嘗試過至少兩種不同的風濕性關節炎用藥治療但是沒有顯著效果的女性類風濕性關節炎患者參與此項持續使用風濕性關節炎用藥及類固醇，並以AVEMAR為輔助治療的研究。在為期一年的研究中發現，患者的症狀在使用六個月後就開始有顯著的改善，並且有約一半的患者能夠減少類固醇的使用量，而且也沒有觀察到任何的副作用產生。這個研究結果顯示，長期使用AVEMAR作為標準治療以外的輔助品有益於類風濕性關節炎的患者。(Balint et al., 2006)
To investigate the effect of the fermented wheat germ extract (Avemar) in patients with severe rheumatoid arthritis (RA). Fifteen female RA (Steinbrocker II-III) patients, who had unsuccessfully tried two different disease-modifying antirheumatic drug (DMARD) treatments, were enrolled in an open-label, 1-year long, pilot clinical study. DMARD and steroid therapies were recorded and continued. All patients received Avemar as additional therapy. For measurement of efficacy the Ritchie Index, the Health Assessment Questionnaire (HAQ) and the assessment of morning stiffness were applied. Patients were evaluated at baseline, 6 and 12 months. For statistical analyses the Wilcoxon test was used. The result indicated the at both 6 and 12 months, Ritchie index, HAQ and morning stiffness showed significant improvements compared with the baseline values. Dosages of steroid could be reduced in about half of the patients. No side effects of Avemar were observed It could be concluded that Supplementation of standard therapies with a continuous administration of Avemar is beneficial for RA patients. (Balint et al., 2006)
